The World Health Organization (WHO) announced today that they have approved a new cervical cancer vaccine. The vaccine is called Cervarix, and it is made by GlaxoSmithKline. Gardasil, made by Merck & Co., had already received WHO’s approval, and Cervarix has now become the second approved vaccine.
Both Cervarix and Gardasil are used as preventative vaccines to help prevent human papillomavirus, also known as HPV. Today’s World Health Organization approval will open doors to many women throughout the world. U.S. News and World Report states, “This is a decision that opens the way for United Nations agencies and partners to purchase millions of doses of the vaccine, Cervarix, for use in developing nations, where most deaths from cervical cancer occur.”
Statistics show that cervical cancer deaths occur in approximately 280,000 women each year. Over 80% of these women live in developing countries. "Cervical cancer affects poor women in the least developed countries more often and more aggressively due to a lack of available screening services and the high prevalence of other serious health conditions such as HIV/AIDS," U.K.-based Glaxo said.
According to the Wall Street Journal, Jean Stephenne, President of GSK Biologicals said "Cervarix can save millions of women's lives throughout the world, but only if it reaches those who need it most."
“Cervarix is available in 97 countries but has not been approved for use in the United States or Japan. The U.S. Food and Drug Administration is expected to make a decision on Cervarix in the next few months,” stated U.S. News and World Report.